NASDAQ:AVXS - AveXis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$217.83 0.00 (0.00 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$217.83
Today's RangeN/A
52-Week Range$65.54 - $217.94
VolumeN/A
Average Volume816,305 shs
Market Capitalization$8.02 billion
P/E Ratio-29.92
Dividend YieldN/A
Beta1.55

About AveXis (NASDAQ:AVXS)

AveXis logoAveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.

Receive AVXS News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXS
CUSIPN/A
Phone847-572-8280

Debt

Debt-to-Equity RatioN/A
Current Ratio8.22
Quick Ratio8.22

Price-To-Earnings

Trailing P/E Ratio-29.92
Forward P/E Ratio-22.48
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$15.46 per share
Price / Book14.09

Profitability

EPS (Most Recent Fiscal Year)($7.28)
Net Income$-218,050,000.00
Net MarginsN/A
Return on Equity-93.95%
Return on Assets-83.75%

Miscellaneous

Employees219
Outstanding Shares36,820,000

AveXis (NASDAQ:AVXS) Frequently Asked Questions

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

How were AveXis' earnings last quarter?

AveXis (NASDAQ:AVXS) announced its earnings results on Wednesday, May, 9th. The company reported ($6.20) earnings per share for the quarter, missing analysts' consensus estimates of ($3.32) by $2.88. View AveXis' Earnings History.

When is AveXis' next earnings date?

AveXis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for AveXis.

What price target have analysts set for AVXS?

19 brokers have issued twelve-month target prices for AveXis' stock. Their predictions range from $52.00 to $171.00. On average, they expect AveXis' stock price to reach $124.5263 in the next year. View Analyst Ratings for AveXis.

What are Wall Street analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:
  • 1. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (5/7/2018)
  • 2. William Blair analysts commented, "We believe that other companies may begin to follow suit and see this as a positive for other AAV companies, most notably in our coverage, Spark (ONCE $62.06; Outperform) and Audentes (BOLD $28.11; Outperform)." (4/9/2018)
  • 3. Mizuho analysts commented, "We expect a pre-BLA meeting in 2Q/3Q18, and potential regulatory approval in 2019 for type 1 SMA. We also see additional upside for AVXS-101 in SMA type 2 patients. KeyPoints Gene therapy is coming of age. After years of advancements and discovery in the field of gene therapy, we believe a number of companies are on the cusp of gaining approval for these novel one-time treatments. We see strong potential for leading candidate products and take confidence from the recent unanimous FDA approval of Spark’s (ONCE, Buy, $79 PT) Luxturna. A significant opportunity for gene therapy in the treatment of SMA. With approximately 60% of the incident SMA population affected by type 1 and limited treatment options, AveXis’ lead product candidate AVXS-101 could have a substantial impact. Given strong data from a recent phase 1 trial, we believe AVXS-101 could capture a significant market share in SMA type 1." (2/12/2018)
  • 4. Chardan Capital analysts commented, "We would encourage buying on any AVXS weakness today, on the potential that the market may have understandably misunderstood what could be an atypical but stepped up process in terms of filing timelines for AVXS-101 in SMA type 1. Our take: Our base case (see our 15 June 2017 note) of a filing after pivotal STR1VE (NCT03306277) phase III data seems to have been improved upon. There are reasons to believe AveXis could file AVXS-101 by 3Q18, with a blue skies" scenario involving AVXS-101 approval by end-2018 or early-2019. We note AveXis’ appropriately non-promotional commentary when executing its duties in communicating status of important regulatory matters to the market." (1/5/2018)

Who are some of AveXis' key competitors?

Who are AveXis' key executives?

AveXis' management team includes the folowing people:
  • Mr. Sean P. Nolan, Chief Exec. Officer, Pres and Director (Age 50)
  • Dr. Sukumar Nagendran M.D., Chief Medical Officer and Sr. VP (Age 51)
  • Mr. Phillip B. Donenberg CPA, Sr. VP, CFO & Principal Accounting Officer (Age 57)
  • Mr. Brian K. Kaspar Ph.D., Chief Scientific Officer, Director and Member of Scientific Advisory Board (Age 44)
  • Mr. Michael B. Johannesen, Chief Compliance Officer, Sr. VP and Gen. Counsel (Age 52)

When did AveXis IPO?

(AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Has AveXis been receiving favorable news coverage?

Media coverage about AVXS stock has trended somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AveXis earned a daily sentiment score of 0.12 on Accern's scale. They also assigned news coverage about the company an impact score of 46.60 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are AveXis' major shareholders?

AveXis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.91%), ADAGE CAPITAL PARTNERS GP, L.L.C. (6.04%), FMR LLC (5.87%), venBio Select Advisor LLC (1.83%), Redmile Group LLC (1.73%) and PointState Capital LP (1.59%). Company insiders that own AveXis stock include Andrew F Knudten, Brian K Kaspar, James J Litalien, Paul B Manning, Sean P Nolan and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

Which institutional investors are selling AveXis stock?

AVXS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Westfield Capital Management Co. LP, Lord Abbett & CO. LLC, Element Capital Management LLC, Barclays PLC, Eaton Vance Management, Eagle Asset Management Inc. and Sivik Global Healthcare LLC. Company insiders that have sold AveXis company stock in the last year include Andrew F Knudten, Brian K Kaspar, James J Litalien, Sean P Nolan and Sukumar Nagendran. View Insider Buying and Selling for AveXis.

Which institutional investors are buying AveXis stock?

AVXS stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, PointState Capital LP, Farallon Capital Management LLC, Franklin Resources Inc., BlackRock Inc., venBio Select Advisor LLC, Frontier Capital Management Co. LLC and Eversept Partners LLC. View Insider Buying and Selling for AveXis.

How do I buy shares of AveXis?

Shares of AVXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AveXis' stock price today?

One share of AVXS stock can currently be purchased for approximately $217.83.

How big of a company is AveXis?

AveXis has a market capitalization of $8.02 billion. The company earns $-218,050,000.00 in net income (profit) each year or ($7.28) on an earnings per share basis. AveXis employs 219 workers across the globe.

How can I contact AveXis?

AveXis' mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company can be reached via phone at 847-572-8280 or via email at [email protected]


MarketBeat Community Rating for AveXis (AVXS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  410
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe AVXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AveXis (NASDAQ:AVXS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for AveXis in the last 12 months. Their average twelve-month price target is $124.5263, suggesting that the stock has a possible downside of 42.83%. The high price target for AVXS is $171.00 and the low price target for AVXS is $52.00. There are currently 1 sell rating, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.262.262.682.65
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $124.5263$124.5263$119.1053$110.5882
Price Target Upside: 42.83% downside41.28% downside2.19% upside15.45% upside

AveXis (NASDAQ:AVXS) Consensus Price Target History

Price Target History for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018Jefferies GroupDowngradeBuy ➝ HoldLowView Rating Details
4/13/2018Chardan CapitalDowngradeBuy ➝ NeutralLowView Rating Details
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$152.00LowView Rating Details
4/12/2018UBSDowngradeBuy ➝ NeutralLowView Rating Details
4/11/2018Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$139.00LowView Rating Details
4/10/2018CitigroupDowngradeBuy ➝ NeutralLowView Rating Details
4/9/2018NomuraUpgradeReduce ➝ NeutralLowView Rating Details
4/9/2018Morgan StanleyDowngradeOverweight ➝ HoldN/AView Rating Details
4/9/2018MizuhoDowngradeBuy ➝ NeutralN/AView Rating Details
4/9/2018William BlairInitiated CoverageOutperform ➝ HoldN/AView Rating Details
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$150.00 ➝ $148.00MediumView Rating Details
2/28/2018Canaccord GenuitySet Price TargetHold ➝ Hold$110.00 ➝ $120.00LowView Rating Details
2/28/2018Wells FargoReiterated RatingOutperform$134.00 ➝ $171.00LowView Rating Details
2/20/2018Sanford C. BernsteinReiterated RatingOutperform$110.00 ➝ $144.00HighView Rating Details
1/9/2018Royal Bank of CanadaReiterated RatingHold$92.00MediumView Rating Details
11/10/2017Bank of AmericaLower Price TargetBuy$115.00 ➝ $112.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingBuy ➝ Buy$130.00N/AView Rating Details
8/29/2017InstinetInitiated CoverageReduce ➝ Reduce$52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$120.00MediumView Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

AveXis (NASDAQ:AVXS) Earnings History and Estimates Chart

Earnings by Quarter for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) Earnings Estimates

2018 EPS Consensus Estimate: ($9.49)
2019 EPS Consensus Estimate: ($12.21)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($2.71)($1.76)($2.24)
Q2 20182($2.86)($1.79)($2.33)
Q3 20182($3.02)($1.81)($2.42)
Q4 20182($3.20)($1.83)($2.52)
Q1 20191($3.25)($3.25)($3.25)
Q2 20191($3.03)($3.03)($3.03)
Q3 20191($3.09)($3.09)($3.09)
Q4 20191($2.84)($2.84)($2.84)

AveXis (NASDAQ AVXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018($2.01)N/AView Earnings Details
5/9/2018Q1 2018($3.32)($6.20)ViewN/AView Earnings Details
2/27/2018Q4 2017($1.64)($2.55)ViewListenView Earnings Details
11/9/2017Q3 2017($1.48)($1.52)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.97)($2.07)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.9450)($1.07)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)($0.92)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.70)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
3/18/2016Q4 2015($0.42)($1.82)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AveXis (NASDAQ:AVXS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AveXis (NASDAQ AVXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 84.14%
Insider Trading History for AveXis (NASDAQ:AVXS)
Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ AVXS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Brian K KasparInsiderSell15,000$119.50$1,792,500.001,767,766View SEC Filing  
4/2/2018James J LitalienVPSell5,000$119.44$597,200.008,800View SEC Filing  
3/7/2018Sean P NolanCEOSell10,000$129.47$1,294,700.0010,000View SEC Filing  
3/1/2018Brian K KasparInsiderSell15,000$126.15$1,892,250.00View SEC Filing  
3/1/2018Sukumar NagendranVPSell1,780$126.19$224,618.20View SEC Filing  
2/1/2018Andrew F KnudtenVPSell2,000$118.13$236,260.007,000View SEC Filing  
2/1/2018Brian K KasparInsiderSell15,000$118.07$1,771,050.001,792,147View SEC Filing  
1/16/2018James J LitalienVPSell5,000$106.52$532,600.00View SEC Filing  
1/2/2018Brian K KasparInsiderSell15,000$109.75$1,646,250.001,808,386View SEC Filing  
1/2/2018Sukumar NagendranVPSell1,780$109.72$195,301.601,780View SEC Filing  
12/4/2017Andrew F KnudtenVPSell2,000$94.48$188,960.007,000View SEC Filing  
12/1/2017Brian K KasparInsiderSell15,000$94.73$1,420,950.001,826,502View SEC Filing  
12/1/2017Sukumar NagendranVPSell1,780$94.77$168,690.601,780View SEC Filing  
11/1/2017Brian K KasparInsiderSell15,000$101.23$1,518,450.001,841,019View SEC Filing  
11/1/2017Sukumar NagendranVPSell1,780$101.26$180,242.801,780View SEC Filing  
10/9/2017Brian K KasparInsiderSell15,000$101.46$1,521,900.00View SEC Filing  
10/2/2017Sukumar NagendranVPSell1,780$97.25$173,105.001,780View SEC Filing  
9/1/2017Sukumar NagendranVPSell1,780$93.25$165,985.001,780View SEC Filing  
8/1/2017Sukumar NagendranVPSell1,780$91.52$162,905.601,780View SEC Filing  
7/3/2017Sukumar NagendranVPSell1,780$81.88$145,746.401,780View SEC Filing  
6/1/2017Sukumar NagendranVPSell1,780$70.91$126,219.801,780View SEC Filing  
5/1/2017Sukumar NagendranVPSell1,780$81.39$144,874.201,780View SEC Filing  
4/3/2017Sukumar NagendranVPSell1,781$76.13$135,587.531,781View SEC Filing  
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AveXis (NASDAQ AVXS) News Headlines

Source:
DateHeadline
Notable ETF Inflow Detected - XBI, AVXS, SRPT, ONCENotable ETF Inflow Detected - XBI, AVXS, SRPT, ONCE
www.nasdaq.com - May 15 at 4:34 PM
AveXis (AVXS) Given Consensus Recommendation of "Hold" by AnalystsAveXis (AVXS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 13 at 11:25 AM
Options Traders Expect Huge Moves in AveXis (AVXS) StockOptions Traders Expect Huge Moves in AveXis (AVXS) Stock
finance.yahoo.com - May 11 at 10:43 AM
Zacks: Analysts Expect AveXis (AVXS) to Announce -$1.99 EPSZacks: Analysts Expect AveXis (AVXS) to Announce -$1.99 EPS
www.americanbankingnews.com - May 8 at 5:12 AM
AveXis (AVXS) Upgraded by Zacks Investment Research to HoldAveXis (AVXS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 7 at 5:28 PM
AveXis (AVXS) Posts  Earnings Results, Misses Expectations By $3.52 EPSAveXis (AVXS) Posts Earnings Results, Misses Expectations By $3.52 EPS
www.americanbankingnews.com - May 4 at 4:37 PM
AveXis: 1Q Earnings SnapshotAveXis: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:36 AM
AveXis Reports First Quarter 2018 Financial and Operating ResultsAveXis Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 3 at 4:14 PM
Audentes Therapeutics Upcoming CatalystsAudentes Therapeutics' Upcoming Catalysts
seekingalpha.com - May 3 at 9:33 AM
AveXis (AVXS) Announces Antitrust Waiting Period Related to Novartis (NVS) Acquisition ExpiredAveXis (AVXS) Announces Antitrust Waiting Period Related to Novartis (NVS) Acquisition Expired
www.streetinsider.com - May 2 at 9:36 AM
AveXis (AVXS) Scheduled to Post Quarterly Earnings on WednesdayAveXis (AVXS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 2:50 AM
Novartis-AveXis Deal Receives U.S. Regulatory ApprovalNovartis-AveXis Deal Receives U.S. Regulatory Approval
www.nasdaq.com - May 1 at 9:42 AM
AveXis Provides Update on Proposed Acquisition by Novartis AGAveXis Provides Update on Proposed Acquisition by Novartis AG
finance.yahoo.com - May 1 at 9:42 AM
3 Things In Biotech, April 26: Taking The Bad With The Good3 Things In Biotech, April 26: Taking The Bad With The Good
seekingalpha.com - April 28 at 10:06 AM
READ NOW: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXSREAD NOW: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
finance.yahoo.com - April 27 at 4:17 PM
AveXis (AVXS) Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1AveXis (AVXS) Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1
www.streetinsider.com - April 25 at 4:27 PM
Late-stage study underway for AVXS-101 in pre-symptomatic spinal muscular atrophyLate-stage study underway for AVXS-101 in pre-symptomatic spinal muscular atrophy
seekingalpha.com - April 25 at 4:27 PM
BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3
www.reuters.com - April 25 at 9:51 AM
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
finance.yahoo.com - April 25 at 9:51 AM
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
finance.yahoo.com - April 25 at 9:51 AM
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of NeurologyAveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
finance.yahoo.com - April 24 at 4:28 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of AveXis, Inc. to Novartis for $218 Per Share is Fair to Shareholders – AVXSINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of AveXis, Inc. to Novartis for $218 Per Share is Fair to Shareholders – AVXS
finance.yahoo.com - April 23 at 4:15 PM
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of AveXis, Inc. BuyoutSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of AveXis, Inc. Buyout
finance.yahoo.com - April 23 at 4:15 PM
REGENXBIO: An Underappreciated Leader In Gene EditingREGENXBIO: An Underappreciated Leader In Gene Editing
seekingalpha.com - April 21 at 9:32 AM
-$1.95 Earnings Per Share Expected for AveXis (AVXS) This Quarter-$1.95 Earnings Per Share Expected for AveXis (AVXS) This Quarter
www.americanbankingnews.com - April 21 at 3:14 AM
A tale of two deals—ahead of earnings, Biogen move perplexesA tale of two deals—ahead of earnings, Biogen move perplexes
finance.yahoo.com - April 20 at 4:19 PM
Novartis AG (NVS) Q1 2018 Earnings Conference Call TranscriptNovartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - April 20 at 9:55 AM
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of NeurologyAveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
globenewswire.com - April 19 at 9:44 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXSSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
finance.yahoo.com - April 19 at 9:44 AM
AveXis Target of Unusually Large Options Trading (AVXS)AveXis Target of Unusually Large Options Trading (AVXS)
www.americanbankingnews.com - April 19 at 8:32 AM
AveXis (AVXS) Given Average Rating of "Hold" by BrokeragesAveXis (AVXS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 11:28 AM
AveXis (AVXS) Cut to Hold at Jefferies GroupAveXis (AVXS) Cut to Hold at Jefferies Group
www.americanbankingnews.com - April 18 at 9:00 AM
Nationwide Children's Hospital reports new highs in tech licensing deals and income from 2017Nationwide Children's Hospital reports new highs in tech licensing deals and income from 2017
finance.yahoo.com - April 17 at 4:39 PM
Novartis Unit Commences Tender Offer For AveXis Stock - Quick FactsNovartis Unit Commences Tender Offer For AveXis Stock - Quick Facts
www.nasdaq.com - April 17 at 10:01 AM
AveXis (AVXS) Earns Outperform Rating from Analysts at Sanford C. BernsteinAveXis (AVXS) Earns Outperform Rating from Analysts at Sanford C. Bernstein
www.americanbankingnews.com - April 15 at 4:30 PM
AveXis Sale: An $8.7 Billion Endorsement for Gene TherapyAveXis Sale: An $8.7 Billion Endorsement for Gene Therapy
www.barrons.com - April 14 at 9:52 AM
AveXis (AVXS) Coverage Initiated at Morgan StanleyAveXis (AVXS) Coverage Initiated at Morgan Stanley
www.americanbankingnews.com - April 13 at 6:39 PM
Do Options Traders Know Something About AveXis (AVXS) Stock We Dont?Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?
finance.yahoo.com - April 13 at 4:17 PM
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBVs Drugs Succeed in Phase IIIPharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
finance.yahoo.com - April 13 at 4:17 PM
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in FocusGene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
finance.yahoo.com - April 13 at 4:17 PM
Pharma M&A Active This Week: 4 Potential Buyout TargetsPharma M&A Active This Week: 4 Potential Buyout Targets
finance.yahoo.com - April 13 at 4:17 PM
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase IIIPharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
finance.yahoo.com - April 13 at 4:17 PM
AveXis (AVXS) Lowered to Neutral at Chardan CapitalAveXis (AVXS) Lowered to Neutral at Chardan Capital
www.americanbankingnews.com - April 13 at 10:37 AM
Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?Do Options Traders Know Something About AveXis (AVXS) Stock We Don't?
finance.yahoo.com - April 13 at 10:10 AM
AveXis (AVXS) "Overweight" Rating Reiterated at Morgan StanleyAveXis' (AVXS) "Overweight" Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - April 12 at 2:52 PM
AveXis (AVXS) Stock Rating Lowered by BarclaysAveXis (AVXS) Stock Rating Lowered by Barclays
www.americanbankingnews.com - April 12 at 10:45 AM
WEISSLAW LLP Investigates AveXis Inc. AcquisitionWEISSLAW LLP Investigates AveXis Inc. Acquisition
www.bizjournals.com - April 12 at 10:39 AM
GSK slims portfolio with sale of rare disease gene therapy drugsGSK slims portfolio with sale of rare disease gene therapy drugs
finance.yahoo.com - April 12 at 10:39 AM
AveXis (AVXS) Rating Lowered to Hold at UBSAveXis (AVXS) Rating Lowered to Hold at UBS
www.americanbankingnews.com - April 12 at 10:19 AM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of AveXis, Inc.- AVXSSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of AveXis, Inc.- AVXS
finance.yahoo.com - April 11 at 10:23 AM

SEC Filings

AveXis (NASDAQ:AVXS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AveXis (NASDAQ:AVXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AveXis (NASDAQ AVXS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.